Boston Institute of Biotechnology and BiBo Pharma Reveal Major Production Expansion for Biologics

Major News in Biologics Production Expansion



The Boston Institute of Biotechnology, LLC (BIB) alongside its sister organization, BiBo Pharma, has announced a significant expansion aimed at transforming the global biologics production landscape. This ambitious endeavor underscores their commitment to leading the contract development and manufacturing organization (CDMO) sector, especially in large-molecule biologics.

Founded in 2014 in Boston, USA, BIB and BiBo Pharma are innovators within the realm of biopharmaceuticals. With their roots firmly planted in the biotechnological hub of Boston, these firms have made remarkable strides in biomanufacturing, recently introducing a game-changing capacity investment that will profoundly enhance their production capabilities.

Expansion Overview



In a bold step for biomanufacturing, BIB and BiBo Pharma have unveiled plans to increase their production capacity significantly. The cornerstone of this expansion is the introduction of a cutting-edge ultra-large stainless steel bioreactor, boasting a remarkable 30,000 liters in working volume. This facility will enable them to handle a total volume exceeding 40,000 liters, marking the dawn of a new era in biologics manufacturing.

Building on this success, the organizations are set to further increase their fermentation capabilities by an impressive 350,000 liters, responding to robust global market demands for ultra-large-scale production.

Details of the New Facilities



The newly constructed facilities will incorporate mammalian cell culture production lines that include:
  • - Four bioreactors of 30,000 liters each,
  • - Two bioreactors of 15,000 liters,
  • - One 5,000-liter perfusion-capable bioreactor.

Moreover, in the microbial fermentation sector, the lines will feature:
  • - Three bioreactors of 30,000 liters,
  • - One 10,000-liter fermentor,
  • - Two fermentors of 3,000 liters.

The culmination of these expansions will significantly boost the overall production capacity of BIB and BiBo Pharma, adding both versatility and efficiency to their operations.

Commitment to ADC Manufacturing Capabilities



As the industry seeks innovative solutions, the firms are also expanding their Antibody-Drug Conjugates (ADC) manufacturing capabilities. They plan to introduce new conjugation workshops capable of accommodating batch sizes up to 5 kg, with an annual production design capacity exceeding 600 kg. Additionally, the organizations are developing a 3,000-liter perfusion production system. This versatile system will serve the diverse needs of their growing client base.

A Complete Biologics Lifecycle



Positioned as a comprehensive CDMO, BIB and BiBo Pharma aim to cover the entire lifecycle of biologics chemistry, manufacturing, and controls (CMC). Their capabilities range from 200 liters to 30,000 liters, utilizing state-of-the-art production technologies, including microbial fermentation and mammalian cell culture. The innovative PanFlex® Engineering system, responsible for pioneering the 30,000-liter stainless steel bioreactor, showcases the firm's commitment to advancing the industry.

The strategic applications of technology, such as the Grand-CHO process platforms and Pulse Continuous Manufacturing, have brought a revolutionary shift in production economics. By enhancing stability and flexibility in their operations, they aim to reduce production costs significantly, from several hundred dollars down to merely $10 per gram, thus solidifying their leadership position.

Looking Ahead



BIB and BiBo Pharma's expansion signifies a pivotal milestone that promises to redefine the standards of biologics manufacturing globally. They are not only poised to meet the ever-increasing demands but also to assist numerous clients in enhancing the competitiveness of their biologic pipelines. Their efforts are dedicated to fostering innovation in biologic manufacturing technologies.

In summary, the Boston Institute of Biotechnology and BiBo Pharma's proactive approach to expanding their production capacity positions them to lead a new wave of advancements in the industry, ultimately benefiting both domestic and international markets significantly.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.